145 related articles for article (PubMed ID: 24374798)
1. Pharmacokinetics of different formulations of oral azacitidine (CC-486) and the effect of food and modified gastric pH on pharmacokinetics in subjects with hematologic malignancies.
Laille E; Savona MR; Scott BL; Boyd TE; Dong Q; Skikne B
J Clin Pharmacol; 2014 Jun; 54(6):630-9. PubMed ID: 24374798
[TBL] [Abstract][Full Text] [Related]
2. A phase I study in patients with solid or hematologic malignancies of the dose proportionality of subcutaneous Azacitidine and its pharmacokinetics in patients with severe renal impairment.
Laille E; Goel S; Mita AC; Gabrail NY; Kelly K; Liu L; Songer S; Beach CL
Pharmacotherapy; 2014 May; 34(5):440-51. PubMed ID: 24877181
[TBL] [Abstract][Full Text] [Related]
3. Results From Phase I Studies Investigating the Dose Linearity of Finerenone Tablets and the Influence of Food or pH-Modifying Comedications on its Pharmacokinetics in Healthy Male Volunteers.
Heinig R; Nagelschmitz J; Loewen S
Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):549-559. PubMed ID: 35612708
[TBL] [Abstract][Full Text] [Related]
4. Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies.
Savona MR; Kolibaba K; Conkling P; Kingsley EC; Becerra C; Morris JC; Rifkin RM; Laille E; Kellerman A; Ukrainskyj SM; Dong Q; Skikne BS
Am J Hematol; 2018 Oct; 93(10):1199-1206. PubMed ID: 30016552
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies.
Laille E; Shi T; Garcia-Manero G; Cogle CR; Gore SD; Hetzer J; Kumar K; Skikne B; MacBeth KJ
PLoS One; 2015; 10(8):e0135520. PubMed ID: 26296092
[TBL] [Abstract][Full Text] [Related]
6. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of a new immediate-release compound omeprazole capsule and its comparison with the enteric-coated formulation under fasting and fed conditions.
Liu Z; Ding L; Zhong S; Cao X; Jiang L; Duan H
Drug Res (Stuttg); 2013 Jul; 63(7):370-5. PubMed ID: 23558602
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer.
Babiker HM; Milhem M; Aisner J; Edenfield W; Shepard D; Savona M; Iyer S; Abdelrahim M; Beach CL; Skikne B; Laille E; Tsai KT; Ho T
Cancer Chemother Pharmacol; 2020 Mar; 85(3):621-626. PubMed ID: 32036412
[TBL] [Abstract][Full Text] [Related]
9. Cinnarizine food-effects in beagle dogs can be avoided by administration in a Self Nano Emulsifying Drug Delivery System (SNEDDS).
Christiansen ML; Holm R; Kristensen J; Kreilgaard M; Jacobsen J; Abrahamsson B; Müllertz A
Eur J Pharm Sci; 2014 Jun; 57():164-72. PubMed ID: 24239996
[TBL] [Abstract][Full Text] [Related]
10. The effect of food on the absorption and pharmacokinetics of rivaroxaban.
Stampfuss J; Kubitza D; Becka M; Mueck W
Int J Clin Pharmacol Ther; 2013 Jul; 51(7):549-61. PubMed ID: 23458226
[TBL] [Abstract][Full Text] [Related]
11. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac.
Kambayashi A; Blume H; Dressman J
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1337-47. PubMed ID: 24056057
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes.
Garcia-Manero G; Gore SD; Kambhampati S; Scott B; Tefferi A; Cogle CR; Edenfield WJ; Hetzer J; Kumar K; Laille E; Shi T; MacBeth KJ; Skikne B
Leukemia; 2016 Apr; 30(4):889-96. PubMed ID: 26442612
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of a novel orodispersible tablet of sildenafil in healthy subjects.
Damle B; Duczynski G; Jeffers BW; Crownover P; Coupe A; LaBadie RR
Clin Ther; 2014 Feb; 36(2):236-44. PubMed ID: 24447534
[TBL] [Abstract][Full Text] [Related]
14. An Open Label, Phase 1, Randomized, Seven-treatment, Seven-period, Crossover Study to Assess the Relative Bioavailability, pH Effect, Food Effect, and Dose Proportionality of CC-292, a Potent and Orally Available Bruton's Tyrosine Kinase Inhibitor.
Cheng Y; Liu L; Xue Y; Zhou S; Li Y
Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):579-592. PubMed ID: 35657581
[TBL] [Abstract][Full Text] [Related]
15. Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH.
Schmitt-Hoffmann A; Desai A; Kowalski D; Pearlman H; Yamazaki T; Townsend R
Int J Clin Pharmacol Ther; 2016 Aug; 54(8):572-80. PubMed ID: 27345284
[TBL] [Abstract][Full Text] [Related]
16. Effect of food intake on the delivery of fluorescein as a model drug in colon delivery capsule after oral administration to beagle dogs.
Matsuda K; Takaya T; Shimoji F; Muraoka M; Yoshikawa Y; Takada K
J Drug Target; 1996; 4(2):59-67. PubMed ID: 8894965
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of the controlled-release nisoldipine coat-core tablet formulation.
Heinig R; Ahr G; Hayauchi Y; Kuhlmann J
Int J Clin Pharmacol Ther; 1997 Aug; 35(8):341-51. PubMed ID: 9266290
[TBL] [Abstract][Full Text] [Related]
18. Sustained relief of chronic pain. Pharmacokinetics of sustained release morphine.
Gourlay GK
Clin Pharmacokinet; 1998 Sep; 35(3):173-90. PubMed ID: 9784932
[TBL] [Abstract][Full Text] [Related]
19. Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor--evidence for dosing flexibility.
Lee RD; Vakily M; Mulford D; Wu J; Atkinson SN
Aliment Pharmacol Ther; 2009 Apr; 29(8):824-33. PubMed ID: 19243357
[TBL] [Abstract][Full Text] [Related]
20. Semagacestat pharmacokinetics are not significantly affected by formulation, food, or time of dosing in healthy participants.
Willis BA; Zhang W; Ayan-Oshodi M; Lowe SL; Annes WF; Sirois PJ; Friedrich S; de la Peña A
J Clin Pharmacol; 2012 Jun; 52(6):904-13. PubMed ID: 21724950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]